Associate Director Millennium: The Takeda Oncology Company Cambridge
Presentation Description: In the past few years, novel multiplex technologies have emerged for spatial profiling of immune phenotypes on a single tissue section. These revolutionary technologies, along with advanced image analysis, enable researchers to identify multiple biological markers simultaneously while understanding the tumor microenvironment, and aid in disease diagnosis. In this talk, results from high-plex MultiOmyx immunofluorescent assay development and verification done on FFPE human tissue samples will be showcased. Furthermore, the capability of technology to identify multiple immune markers along with cytokines using RNAScope in-situ hybridization method will be elaborated. Lastly, advanced spatial analytical tools, used to profile samples from patients with NSCLC and duodenal biopsies (celiac patients) will be discussed. This novel multiplex technology has given us multiple choices for designing biomarker panels for each clinical trial. Multiplex technologies further maximize the use of limited clinical biopsies for evaluation of TME, drug response, and future combination strategies for cancer therapy.
Upon completion, participant will be able to learn about high-plex immune profiling technology and implementation for clinical trial to evaluate FFPE biopsies. Define Immune-phenotypes in single biopsy slide.
Describes the importance of spatial information in the immuno-oncology therapy. Looking at numbers is not enough, the proximity of immune cells to the tumor cells is important.
Will demonstrate the use of combining multiplex immunofluorescent technology with RNAScope in-situ hybridization to identify activated immune cells by looking at cytokine expression.